摘要
目的观察吗啡缓释片联合汉防己甲素片治疗重度癌性疼痛的临床效果。方法将60＂N重度癌性疼痛患者按数字随机分为观察组和对照组，每组各30例。对照组给予吗啡缓释片治疗，观察组在对照组基础上联合汉防己甲素片进行治疗，疗程2周，观察癌性疼痛得到有效控制所需的时间和每日有效剂量，爆发痛发生次数及短效吗啡的用量，NRS评分及不良反应。结果观察组癌痛得到有效控制所需时间明显短于对照组（P〈0．05），观察组吗啡缓释片每日有效剂量明显低于对照组（P〈0．05）；1周内爆发痛发生次数与吗啡即释片观察组也少于对照组（P〈0．05），两组治疗后NRS评分均明显得到改善（P〈0．05），而观察组优于对照组（P〈0．05），且观察组不良反应较少（P〈0．05）。结论吗啡缓释片联合汉防己甲素片治疗重度癌性疼痛能增加疗效，减少吗啡缓释片每日有效剂量，缩短癌痛有效控制的时间并减少不良反应。
Objective To explore the clinical effect of morphine sustained-release tablets combined with tetrandrine in the treatment of severe cancer pain. Methods 60 patients with severe cancer pain were randomly assigned into two groups, substained-release morphine tablets combined with tetrandrine group （ 30cases ） and the single-agent substained-release morphine tablets group （ 30 cases ） . After 2 weeks, the analgesic relief time, analgesic duration, daily dosage of morphine sustained-release tablets, number of bursts of pain, dosage of short effective morphine, numerical rating scale, and the incidence of adverse reactions were compared between two groups. Results The treatment group＇s onset time was shorter than that of the control group while the daily dosage was less than that one （ P〈0.05 ） in the control group （ P〈0.05 ） .In a week, The treatment group＇s number of bursts of pain and dosage of short effective morphine was less than that in the control group. Compared with those before treatment, both two groups＇ numerical rating scale （ NRS ） score were decreased, the treatment group＇s was better than the control group＇s （P〈0.05） .Compared with the control group, the treatment group had less adverse reactions （ P〈0.05 ） . Conclusions Morphine sustained-release tablets combined with tetrandrine in the treatment of patients with severe cancer pain improves the curative effects, reduces the average daily dose of morphine sustained-release tablets, and reduces the adverse reactions.
出处
《浙江临床医学》
2018年第2期293-294,共2页
Zhejiang Clinical Medical Journal
关键词
吗啡缓释片
汉防己甲素
癌性疼痛
Morphine sustained-release tablets Tetrandrine Cancer pain
